Search company, investor...

Predict your next investment

Venture Capital
FINANCE | Investment Firms & Funds
sofimacinnovation.com

Investments

132

Portfolio Exits

32

Funds

12

About Sofimac Innovation

Sofimac Innovation, formerly iSource is a French venture capital firm specializing in early stage investments. The firm invests primarily in early stage companies in Information and Communication Technologies. Such companies develop software, design telephony components, provide new Internet services, create new multimedia experiences, and so forth.

Headquarters Location

23 avenue d’iéna

Paris, 75116,

France

+33 (0)1 45 01 46 46

Want to inform investors similar to Sofimac Innovation about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Sofimac Innovation News

DeepUII Raises $13 Million to Bring its Sepsis Platform to Market

Oct 21, 2022

This is not the first round of funding DeepUII has closed. In July 2020, the company raised its first round of €3.5 million with the support of Alta Life Sciences, Kurma Partners, and Sofimac Innovation, through its Pertinence Invest 2 fund. With that capital injection, the company could cover the financial needs to validate the technology and start the development of the first equipment. 0 DeepUll is once again raising capital . The Spanish company specializing in diagnostic solutions has closed a €13 million financing round in order to move forward with its sepsis early detection platform, company sources said. The financing round has been led by new investors Innvierte, which is part of the Ministry of Science and Innovation, and another investor whose name has not been disclosed. The round has also counted with the participation of current partners Kurma Partners, Alta Life Sciences, UI Investissement, and Axis Participaciones Empresariales. The company, based at the Barcelona Science Park (PCB), will use this capital injection to accelerate the market launch of its first-in-class platform for the early diagnosis of sepsis. Read more about DeepUII with our companion app. Born2Invest is a digital media website covering the biotech industry, among others. Our companion app allows you to get your daily dose of financial news from industries like banking, cannabis, and innovation in biotechnology. DeepUII has raised more than €15 million in private funding since its inception DeepUll was born in 2020 to create fast, affordable, and accessible diagnostic solutions with a specific focus on culture-free diagnostics to be able to detect sepsis even before the onset of symptoms. The Catalan company was born out of the hands of Jordi Carrera and Rafel Bru, who had previously founded Stat-Dx, which they sold in 2018 to Qiagen for $191 million (€154 million). Stat-DX developed a diagnostic test capable of processing any type of sample without prior preparation and facilitating the result of up to 48 molecular targets simultaneously. DeepUll’s sepsis product is designed to detect more than 250 different pathogens and fifteen resistance genes in one hour from 10 milliliters of blood. The product will generate phenotypic antimicrobial susceptibility results, without the need for positive blood culture. The product will be a fully automated device so that it can be placed in any clinical setting, such as a laboratory, emergency, or intensive care unit (ICU). DeepUll’s sepsis product is designed to detect more than 250 pathogens This is not the first round of funding DeepUII has closed. In July 2020, the company raised its first round of €3.5 million with the support of Alta Life Sciences, Kurma Partners, and Sofimac Innovation, through its Pertinence Invest 2 fund. With that capital injection, the company could cover the financial needs to validate the technology and start the development of the first equipment. Sepsis causes around eleven million deaths annually, surpassing as of 2018 the estimate of 9.6 million deaths caused by cancer. Sepsis occurs when the body’s immune system response to infection becomes dysregulated. This can cause a cascade of changes that damage multiple organs, leading them to fail, sometimes even resulting in death. __ DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our  disclaimer  for more information. This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these  important disclosures . First published in  PlantaDoce , a third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the original will prevail. Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Sofimac Innovation Investments

132 Investments

Sofimac Innovation has made 132 investments. Their latest investment was in Aisprid as part of their Seed VC on June 6, 2021.

CBI Logo

Sofimac Innovation Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/30/2021

Seed VC

Aisprid

$5.45M

Yes

3

6/16/2021

Seed

Buldi

$1.68M

Yes

3

4/14/2021

Unattributed VC - II

Nestwave

$2.9M

No

11

3/19/2021

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

3/1/2021

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/30/2021

6/16/2021

4/14/2021

3/19/2021

3/1/2021

Round

Seed VC

Seed

Unattributed VC - II

Seed VC

Seed VC

Company

Aisprid

Buldi

Nestwave

Subscribe to see more

Subscribe to see more

Amount

$5.45M

$1.68M

$2.9M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

3

11

10

10

Sofimac Innovation Portfolio Exits

32 Portfolio Exits

Sofimac Innovation has 32 portfolio exits. Their latest portfolio exit was LeddarTech on June 13, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/13/2023

Acq - Pending

$99M

3

5/3/2023

Acquired

$99M

3

3/20/2023

Acquired

$99M

3

3/16/2023

Corporate Majority

Subscribe to see more

$99M

Subscribe to see more

10

10/31/2022

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/13/2023

5/3/2023

3/20/2023

3/16/2023

10/31/2022

Exit

Acq - Pending

Acquired

Acquired

Corporate Majority

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

3

3

3

10

10

Sofimac Innovation Fund History

12 Fund Histories

Sofimac Innovation has 12 funds, including Relevance Invest 2.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/8/2020

Relevance Invest 2

$46.31M

1

12/13/2012

Angel Source

Early-Stage Venture Capital

Open

$25.98M

1

6/15/2009

FCPI CAAM Investissement 1

Early-Stage Venture Capital

Closed

$8.49M

1

12/26/2008

FCPI CAAM INNOVATION 9

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2007

I-Source 3

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

6/8/2020

12/13/2012

6/15/2009

12/26/2008

12/31/2007

Fund

Relevance Invest 2

Angel Source

FCPI CAAM Investissement 1

FCPI CAAM INNOVATION 9

I-Source 3

Fund Type

Early-Stage Venture Capital

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Open

Closed

Subscribe to see more

Subscribe to see more

Amount

$46.31M

$25.98M

$8.49M

$99M

$99M

Sources

1

1

1

10

10

Sofimac Innovation Team

4 Team Members

Sofimac Innovation has 4 team members, including current Managing Partner, Didier Moret.

Name

Work History

Title

Status

Didier Moret

Managing Partner

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Didier Moret

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Managing Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.